1620: Targeting Immune Cells as a Novel Treatment for Canine Atopic Dermatitis

Grant Status: Closed

Grant Amount: $77,039
Dr. Daniel A. Gingerich, D.V.M., Imulan Bio Therapeutics, LLC
January 1, 2012 - December 31, 2013
Sponsor(s): American Shih Tzu Club, Inc., French Bulldog Club of America, Great Pyrenees Club of America, National Beagle Club, Westie Foundation of America, Inc.
Breed(s): -All Dogs
Research Program Area: Dermatology and Allergic Disease

Project Summary

Introduction: T-cell receptor (TCR) peptides are known to have immunomodulatory and immunoregulatory properties. Use of TCR peptides for treating canine atopic dermatitis, a prevalent condition in dogs, was evaluated in this double blind, placebo controlled study.

Study Design and Methods: This was a prospective, multi-site, double-blind, randomized study that evaluated the clinical effects of TCR peptide in 62 client-owned dogs with persistent, severe, atopic dermatitis. Dogs were randomly allocated into 3 treatment groups, Group A (100mg), Group B (25mg) or Group C (placebo). Treatments were administered subcutaneously at baseline and Week 2, and dogs were evaluated for efficacy and safety at baseline, Week 2 and Week 6 using standardized score forms for itchiness, redness, abrasion, hair loss, and overall severity and adverse events. Complete blood counts, chemistry, and anti- TCR titer measurements were taken at baseline and Week 6.

Results: Group A had significant improvement (p <0.05) over time for skin redness (erythema), Group B had significant improvement in itchiness (pruritus) over time, and combined treatment groups (A and B) had significant improvements (p<0.05) over time in pruritus and erythema scores, whereas placebo Group C showed no significant improvement in any parameter.
Significant increases in anti-TCR titers at week 6 were detected in Group A (TCR 100mg) but not in other groups. There were no alterations in blood chemistry or hematology parameters in any group. Side effects were reported in only 6 of the 62 dogs, none serious.

Conclusions: Consistent with previous studies, the TCR peptide appears to have clinical benefits in dogs with signs of atopic dermatitis. The overall improvements were less than anticipated, and may be associated with a reduction in potency owing to a new peptide manufacturing process. TCR peptide therapy is well tolerated; no toxicity was detected. Further studies in optimizing the potency, manufacturing and dosage are warranted.

Publication(s)

None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Make an Investment Today:

  • $50
  • $100
  • $250
  • $1000
  • Give Now
Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2016 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software